| pubmed-article:18480009 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18480009 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:18480009 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:18480009 | lifeskim:mentions | umls-concept:C0699885 | lld:lifeskim |
| pubmed-article:18480009 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:18480009 | lifeskim:mentions | umls-concept:C0332391 | lld:lifeskim |
| pubmed-article:18480009 | lifeskim:mentions | umls-concept:C0663937 | lld:lifeskim |
| pubmed-article:18480009 | lifeskim:mentions | umls-concept:C0694894 | lld:lifeskim |
| pubmed-article:18480009 | lifeskim:mentions | umls-concept:C1420433 | lld:lifeskim |
| pubmed-article:18480009 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:18480009 | lifeskim:mentions | umls-concept:C1424666 | lld:lifeskim |
| pubmed-article:18480009 | lifeskim:mentions | umls-concept:C1415887 | lld:lifeskim |
| pubmed-article:18480009 | lifeskim:mentions | umls-concept:C1419040 | lld:lifeskim |
| pubmed-article:18480009 | lifeskim:mentions | umls-concept:C1421834 | lld:lifeskim |
| pubmed-article:18480009 | lifeskim:mentions | umls-concept:C0598086 | lld:lifeskim |
| pubmed-article:18480009 | lifeskim:mentions | umls-concept:C0598388 | lld:lifeskim |
| pubmed-article:18480009 | lifeskim:mentions | umls-concept:C0004083 | lld:lifeskim |
| pubmed-article:18480009 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:18480009 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:18480009 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:18480009 | pubmed:dateCreated | 2008-5-15 | lld:pubmed |
| pubmed-article:18480009 | pubmed:abstractText | TSC1/hamartin is a tumor suppressor gene involved in the development of various malignancies, including bladder cancer. In vitro studies showed that hamartin controls cell proliferation partly by up-regulating p27 and 14-3-3sigma. This study was designed to explore the value of these biomarkers in predicting outcome in pTa/pT1 tumors and validate the regulation of p27 and 14-3-3sigma by hamartin in vivo using human bladder cancer tissue. A tissue microarray of 134 pTa and pT1 tumors was constructed, and sections were stained with hamartin, 14-3-3sigma, and p27 antibodies. In multiple Cox regression analysis, pTa/pT1 tumors with reduced or low expression of hamartin tended to have higher risk of progression (P = .030). High-grade tumors tended to be at higher risk of progression in comparison with low-grade tumors (P < .001). The combination of expression of these 3 biomarkers did not add predictive value regarding disease outcomes. Low hamartin expression and high tumor grade are independent factors in predicting faster pTa/pT1 tumor progression. In a subset of pTa/pT1 tumors, hamartin has a role in bladder carcinogenesis by positively regulating 14-3-3sigma and p27. | lld:pubmed |
| pubmed-article:18480009 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18480009 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18480009 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:18480009 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18480009 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18480009 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18480009 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18480009 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18480009 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18480009 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18480009 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18480009 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18480009 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18480009 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:18480009 | pubmed:issn | 0002-9173 | lld:pubmed |
| pubmed-article:18480009 | pubmed:author | pubmed-author:HerrmannFranç... | lld:pubmed |
| pubmed-article:18480009 | pubmed:author | pubmed-author:BeckAmyA | lld:pubmed |
| pubmed-article:18480009 | pubmed:author | pubmed-author:AlvarezVictor... | lld:pubmed |
| pubmed-article:18480009 | pubmed:author | pubmed-author:Mhawech-Fauce... | lld:pubmed |
| pubmed-article:18480009 | pubmed:author | pubmed-author:FischerGaborG | lld:pubmed |
| pubmed-article:18480009 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18480009 | pubmed:volume | 129 | lld:pubmed |
| pubmed-article:18480009 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18480009 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18480009 | pubmed:pagination | 918-23 | lld:pubmed |
| pubmed-article:18480009 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:18480009 | pubmed:meshHeading | pubmed-meshheading:18480009... | lld:pubmed |
| pubmed-article:18480009 | pubmed:meshHeading | pubmed-meshheading:18480009... | lld:pubmed |
| pubmed-article:18480009 | pubmed:meshHeading | pubmed-meshheading:18480009... | lld:pubmed |
| pubmed-article:18480009 | pubmed:meshHeading | pubmed-meshheading:18480009... | lld:pubmed |
| pubmed-article:18480009 | pubmed:meshHeading | pubmed-meshheading:18480009... | lld:pubmed |
| pubmed-article:18480009 | pubmed:meshHeading | pubmed-meshheading:18480009... | lld:pubmed |
| pubmed-article:18480009 | pubmed:meshHeading | pubmed-meshheading:18480009... | lld:pubmed |
| pubmed-article:18480009 | pubmed:meshHeading | pubmed-meshheading:18480009... | lld:pubmed |
| pubmed-article:18480009 | pubmed:meshHeading | pubmed-meshheading:18480009... | lld:pubmed |
| pubmed-article:18480009 | pubmed:meshHeading | pubmed-meshheading:18480009... | lld:pubmed |
| pubmed-article:18480009 | pubmed:meshHeading | pubmed-meshheading:18480009... | lld:pubmed |
| pubmed-article:18480009 | pubmed:meshHeading | pubmed-meshheading:18480009... | lld:pubmed |
| pubmed-article:18480009 | pubmed:meshHeading | pubmed-meshheading:18480009... | lld:pubmed |
| pubmed-article:18480009 | pubmed:meshHeading | pubmed-meshheading:18480009... | lld:pubmed |
| pubmed-article:18480009 | pubmed:meshHeading | pubmed-meshheading:18480009... | lld:pubmed |
| pubmed-article:18480009 | pubmed:meshHeading | pubmed-meshheading:18480009... | lld:pubmed |
| pubmed-article:18480009 | pubmed:meshHeading | pubmed-meshheading:18480009... | lld:pubmed |
| pubmed-article:18480009 | pubmed:meshHeading | pubmed-meshheading:18480009... | lld:pubmed |
| pubmed-article:18480009 | pubmed:meshHeading | pubmed-meshheading:18480009... | lld:pubmed |
| pubmed-article:18480009 | pubmed:meshHeading | pubmed-meshheading:18480009... | lld:pubmed |
| pubmed-article:18480009 | pubmed:meshHeading | pubmed-meshheading:18480009... | lld:pubmed |
| pubmed-article:18480009 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18480009 | pubmed:articleTitle | Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma. | lld:pubmed |
| pubmed-article:18480009 | pubmed:affiliation | Department of Pathology and Laboratory Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. | lld:pubmed |
| pubmed-article:18480009 | pubmed:publicationType | Journal Article | lld:pubmed |
| entrez-gene:7248 | entrezgene:pubmed | pubmed-article:18480009 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:18480009 | lld:entrezgene |
| lhgdn:association:40106 | lhgdn:found_in | pubmed-article:18480009 | lld:lhgdn |
